• New targeted treatment option now available in for adult patients with BRAF^V600E mutant advanced non-small cell lung cancer (NSCLC)
• Launch follows European approval based on results from the Phase II PHAROS trial, demonstrating meaningful clinical benefit to patients with a high objective response rate (ORR)

Laboratoires Pierre Fabre Singapore is delighted to announce the access for patients to BRAFTOVI^® (encorafenib) in combination with MEKTOVI^® (binimetinib) for the treatment of adult patients with advanced NSCLC with a BRAF^V600E mutation.

It follows the European Commission (EC) approval that was based on the results from the Phase II PHAROS trial, a global, open-label, multicentre, non-randomised trial to determine the efficacy and safety of BRAFTOVI^® + MEKTOVI^® in 98 patients from 56 study centres across 5 countries.^1,2

Lung cancer is the leading cause of cancer-related deaths, with 1,278 deaths in Singapore annually, and 1,942 new cases diagnosed every year whereby 1-2% of NSCLC are BRAF^V600E mutant.^3,4

"We are delighted to be able to bring BRAFTOVI^® + MEKTOVI^® to NSCLC patients with a BRAF^V600E mutation in Singapore. This approval from Health Sciences Authority (HSA) is a significant milestone as BRAFTOVI^® + MEKTOVI^® will give patients the option of an additional effective targeted therapy. This is a further demonstration of our commitment to addressing the most critical needs in cancer care today through the delivery of clinically meaningful treatments," said Jairo Pardey, General Manager Laboratoires Pierre Fabre, Singapore.